Company Analysis

Search the recordFBRXCtrl K

Forte Biosciences, Inc. (FBRX)

FBRX · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2007

Full chart Alerts Compare

Grade4.8

◀ Past 3.3● Present 3.7▶ Future 6.8

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2019, as filed

Revenue$36,000-99.8%

Net income-$4.1M+91.7%

Earnings per sharen/a

Operating cash flow-$2.8M+92.0%

Cash$6.9M-83.0%

Debtn/a

Shareholders’ equity-$4.8M-548.0%

Shares, dilutedn/a

Return on equity-113.8%

The recordfrom its filings

Filings in 2026107

Newest filingNov 4 · SCHEDULE 13G/A

Annual reportMar 31, 2026

Quarterly reportAug 12, 2026

Next report due10-Q by Nov 14

Insider sales, 12 months$0.00

Insider buys, 12 months$300,000

Patents granted13

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Jun 2026Net income -$87.9MCash from operations -$72.0Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Sep 8, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Sep 8, 2026 · SEC EDGAR · Form 15-12G

Deregistration notice

Open the filing on sec.gov

Sep 8, 2026 · SEC EDGAR · Form 15-12G

Deregistration notice

Open the filing on sec.gov

Sep 8, 2026 · SEC EDGAR · Form 15-12G

Deregistration notice

Open the filing on sec.gov

Sep 1, 2026 · SEC EDGAR · Form EFFECT

Registration effective

Open the filing on sec.gov

Sep 1, 2026 · SEC EDGAR · Form EFFECT

Registration effective

Open the filing on sec.gov

Sep 1, 2026 · SEC EDGAR · Form EFFECT

Registration effective

Open the filing on sec.gov

Sep 1, 2026 · SEC EDGAR · Form EFFECT

Registration effective

Open the filing on sec.gov

Sep 1, 2026 · SEC EDGAR · Form EFFECT

Registration effective

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Forte Biosciences, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Dallas, TX.

Newest on the record

Large holder update, amended on Nov 4. Before it, large holder update, amended on Sep 8.

What is due next

The 10-Q for the period to Sep 30, 2026, due by Nov 14, 2026.

About FBRX

Forte Biosciences, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Dallas, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported a loss of $69 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersDallas, TX

Business modelPre-revenue company

Filing since2007

Fiscal year endsDec 31

SEC number (CIK)1419041

Peers on fileRFL, SCNX, EPRX, RADX

Financial performance

In fiscal 2019 Forte Biosciences’s revenue was $36,000, down 99.8% from $18.04 million the year before. It made a net loss of $4.07 million.

Annual report, filed Mar 31, 2026.

Financial statements

The grade

Forte Biosciences grades 4.8 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past3.3

● Present3.7

▶ Future6.8

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton FBRX · research, not advice